HIV Research Today is a free monthly online journal that collates and summarizes the latest research about HIV, including details on human immunodeficiency virus, testing, treatment, prevention, vaccines, aids.

Can routine clinical markers be used longitudinally to monitor antiretroviral therapy success in resource-limited settings?

Bagchi S, Kempf MC, Westfall AO, Maherya A, Willig J, Saag MS

Division of Geographic Medicine and Center for AIDS Research, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.

Although routine clinical markers are used routinely to determine the stage of human immunodeficiency virus (HIV) disease, their use in monitoring response to antiretroviral therapy is poorly defined. Selected clinical markers were evaluated for their ability to predict first-line antiretroviral therapy success. No clinically meaningful variables were identified that predicted virologic or immunological success, implying that the CD4+ cell count and HIV type 1 RNA level data are required for optimal management of antiretroviral therapy.

Published 4 December 2006 in Clin Infect Dis, 44(1): 135-8.
Full-text of this article is available online (may require subscription).

© 2004-2008 HIV Research Today. All Rights Reserved.